Marcel Schmude

Marcel Schmude

Auto-generated profile, based on publicly available information

Marcel Schmude

Ada Health GmbH, Neue Grünstraße 17, Berlin, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
MSMarcel Schmude
Marcel Schmude
NMNAHYA SALIM MASOUD
NAHYA SALIM MASOUD
HAHila Azadzoy
Hila Azadzoy
MBMustafa Bane
Mustafa Bane
EMElizabeth Millen
Elizabeth Millen
SGStephen Gilbert
Stephen Gilbert
Background: Low- and middle-income countries face difficulties in providing adequate health care. One of the reasons is a shortage of qualified health workers. Diagnostic decision support systems are designed to aid clinicians in their work and have the potential to mitigate pressure on health care systems. Objective: The Artificial Intelligence–Based Assessment of Health Symptoms in Tanzania (AFYA) study will evaluate the potential of an English-language artificial intelligence–based prototype diagnostic decision support system for mid-level health care practitioners in a low- or middle-income setting. Methods: This is an observational, prospective clinical study conducted in a busy Tanzanian district hospital. In addition to usual care visits, study participants will consult a mid-level health care practitioner, who will use a prototype diagnostic decision support system, and a study physician. The accuracy and comprehensiveness of the differential diagnosis provided by the diagnostic decision support system will be evaluated against a gold-standard differential diagnosis provided by an expert panel. Results: Patient recruitment started in October 2021. Participants were recruited directly in the waiting room of the outpatient clinic at the hospital. Data collection will conclude in May 2022. Data analysis is planned to be finished by the end of June 2022. The results will be published in a peer-reviewed journal. Conclusions: Most diagnostic decision support systems have been developed and evaluated in high-income countries, but there is great potential for these systems to improve the delivery of health care in low- and middle-income countries. The findings of this real-patient study will provide insights based on the performance and usability of a prototype diagnostic decision support system in low- or middle-income countries. Trial Registration: ClinicalTrials.gov NCT04958577; http://clinicaltrials.gov/ct2/show/NCT04958577 International Registered Report Identifier (IRRID): DERR1-10.2196/34298

16 June 2026 in Nature Health
Verified
Journal Article
Open access
MSMarcel Schmude
Marcel Schmude
SGStephen Gilbert
Stephen Gilbert
CLCaroline Moor Larsson
Caroline Moor Larsson
NGNoxolo Gqada
Noxolo Gqada
KLKris Lemon
Kris Lemon
FCFabienne Cotte
Fabienne Cotte
High maternal mortality rates persist as a critical challenge in low-resource settings. Here, in this prospective, observational mixed-methods study, we evaluated a Diagnostic Decision Support System integrated into MomConnect, South Africa’s government-led WhatsApp-based maternal health platform. Between May and June 2023, 968 pregnant women and mothers were enrolled, of whom 86.3% faced multiple barriers to care. Behaviour was assessed via platform surveys and phone interviews at 1-week follow-up. A physician panel rated Diagnostic Decision Support System advice safe in 98.4% (181/184; P < 0.001) of cases. After use, 44.6% (266/596) changed care-seeking intentions, and uncertainty dropped from 17.3% to 6.0%. By follow-up, 43.0% (337/785) had sought care, up from 17.0% initially. Safe behaviours increased by 18.1% ( P = 0.001) and appropriate behaviour by 10.5% ( P = 0.053). Half of those receiving treatment had not initially planned to seek care. Integrating clinical artificial intelligence into a government health platform was associated with safe advice and improved health-seeking behaviour. ClinicalTrials.gov: NCT06790069; funded by the Rockefeller Foundation.

11 April 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
EMElizabeth Millen
Elizabeth Millen
NSNahya Salim
Nahya Salim
HAHila Azadzoy
Hila Azadzoy
MBMustafa Miraji Bane
Mustafa Miraji Bane
LOLisa O'DOnnell
Lisa O'DOnnell
SGStephen Henry Gilbert
Stephen Henry Gilbert
Introduction Due to a global shortage of healthcare workers, there is a lack of basic healthcare for 4 billion people worldwide, particularly affecting low-income and middle-income countries. The utilisation of AI-based healthcare tools such as symptom assessment applications (SAAs) has the potential to reduce the burden on healthcare systems. The purpose of the AFYA Study (AI-based Assessment oF health sYmptoms in TAnzania) is to evaluate the accuracy of the condition suggestions and urgency advice provided by a user on a Swahili language Ada SAA. Methods and analysis This study is designed as an observational prospective clinical study. The setting is a waiting room of a Tanzanian district hospital. It will include patients entering the outpatient clinic with various conditions and age groups, including children and adolescents. Patients will be asked to use the SAA before proceeding to usual care. After usual care, they will have a consultation with a study-provided physician. Patients and healthcare practitioners will be blinded to the SAA’s results. An expert panel will compare the Ada SAA’s condition suggestions and urgency advice to usual care and study provided differential diagnoses and triage. The primary outcome measures are the accuracy and comprehensiveness of the Ada SAA evaluated against the gold standard differential diagnoses. Ethics and dissemination Ethical approval was received by the ethics committee (EC) of Muhimbili University of Health and Allied Sciences with an approval number MUHAS-REC-09-2019-044 and the National Institute for Medical Research, NIMR/HQ/R.8c/Vol. I/922. All amendments to the protocol are reported and adapted on the basis of the requirements of the EC. The results from this study will be submitted to peer-reviewed journals, local and international stakeholders, and will be communicated in editorials/articles by Ada Health. Trial registration number NCT04958577.


13 March 2026 in Journal of Neurology
Verified
Journal Article
Open access
EFEmma Fröling
Emma Fröling
MSMariel Morales Sahm
Mariel Morales Sahm
MSMarcel Schmude
Marcel Schmude
CACharlotte P. Assies
Charlotte P. Assies
MWMichael Wittenberg
Michael Wittenberg
TRThomas Günther Riemer
Thomas Günther Riemer
Objective: To synthesize adverse event (AE) data from randomized controlled trials (RCTs) of levetiracetam (LEV) and brivaracetam (BRV), compare their safety profiles, and identify moderators of AE risk. Methods: We conducted a systematic review and meta-analysis of RCTs of LEV or BRV, searching PubMed, Web of Science, and ClinicalTrials.gov to August 2025. AE frequencies were summarized qualitatively, and random-effects meta-analyses compared LEV and BRV with placebo. Additional analyses compared LEV and BRV and assessed moderators. PROSPERO: CRD42023491050, CRD420251003207. Results: Ninety-six RCTs including 7145 patients exposed to LEV and 2549 to BRV were analyzed. Qualitative synthesis identified headache, somnolence, dizziness, and fatigue as the most common AEs, with higher frequencies of some psychiatric AEs (e.g., irritability, aggression) reported for LEV. Meta-analyses showed increased somnolence with both LEV (OR 1.80, 95% CI [1.41–2.30]) and BRV (OR 1.86, 95% CI [1.33–2.61]). LEV was additionally associated with irritability (OR 2.55, 95% CI [1.41–4.63]) and asthenia (OR 1.71, 95% CI [1.15–2.54]), whereas BRV was associated with dizziness (OR 1.75, 95% CI [1.24–2.46]) and fatigue (OR 2.14, 95% CI [1.43–3.20]). Few moderators of AE risk were identified, and no significant differences emerged between LEV and BRV in indirect comparisons. Conclusion: LEV and BRV show favorable safety profiles that appear comparable based on meta-analytic findings, despite higher rates of some psychiatric AEs with LEV on a descriptive level. Both remain safe treatment options, though larger head-to-head trials are needed to provide definitive comparative evidence.

21 May 2026 in npj Digital Medicine
Verified
Journal Article
Open access
APAndreia Pimenta
Andreia Pimenta
NKNisha Kini
Nisha Kini
FCFabienne Cotte
Fabienne Cotte
FLFilipa Dias Lourenço
Filipa Dias Lourenço
MPMiguel Paiva Pereira
Miguel Paiva Pereira
PFPedro Flores
Pedro Flores
Digital front doors combining symptom assessment and self-triage are increasingly used, yet real-world evidence on their clinical integration remains limited. This prospective post-market clinical follow-up evaluated a clinical decision support system embedded in routine care within a large private healthcare network. Adults completed a structured symptom assessment before consultation, and both participants and physicians completed predefined questionnaires. Treating physicians generally judged the urgency advice and assessment report to be appropriate. When the report was reviewed before the consultation, physicians reported greater preparedness and perceived efficiency gains. Participants generally reported complete symptom capture and improved preparedness. These findings provide prospective real-world evidence that a symptom assessment CDSS can generate appropriate outputs in routine care and may support both patient preparation and clinician workflow when integrated into practice.